Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Brief description of study
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyloid Cardiomyopathy
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female Aged 18 and older Amyloid Cardiomyopathy
Updated on
09 Mar 2024.
Study ID: 849568
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
